Suche
hier klicken, um den Ort für die Startseite festzulegen
Berlin
17
MI 7° / 17°
DO 11° / 19°
Dax6.305-1,4% TDax755-1,2% Dow12.453-1,0% NAS2.526-1,3% N2258.633-0,3% Öl88,51-2,5%
DB-Dax6.286-1,7% ESX2.126-1,6% S&P1.317-1,2% NasF2.527-1,3% EUR1,2423-0,5% Gold1.540,82-0,9%

Ad-hoc Meldungen und Investor Relations

Biofrontera AG:Ad hoc: Biofrontera AG - 500,000 shares subscribed in capital increase


Biofrontera AG /
/
Ad hoc: Biofrontera AG - 500,000 shares subscribed in capital increase
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Leverkusen, 3 February 2012 - Management and supervisory board of Biofrontera AG
have decided to increase the company's base capital from EUR 11,240,486.00 by up
to Euro 500,000.00 to up to EUR 11,740,486.00 through issuing 500,000 new
ordinary shares from authorized capital II. The purchase right of the
shareholders was excluded. According to today's tabulation, the private
placement of the shares was successfully completed and over-subscribed. The
registration of the shares will follow shortly. The proceeds of the capital
increase amount to about EUR 1.5 mln.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact:
Werner Pehlemann
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail:w.pehlemann@biofrontera.com


--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;





This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biofrontera AG via Thomson Reuters ONE

[HUG#1582430]